[68Ga]Ga-HTK03149 PET/CT for Disease Attributes

Phase-Based Estimates
1
Effectiveness
1
Safety
BC Cancer, Vancouver, Canada
Disease Attributes+5 More
[68Ga]Ga-HTK03149 PET/CT - Other
Eligibility
18+
Male
Eligible conditions
Disease Attributes

Study Summary

This study is evaluating whether a radiotracer can be safely used to image prostate cancer.

See full description

Eligible Conditions

  • Disease Attributes
  • Prostatic Diseases
  • Urogenital Neoplasms
  • Prostate Cancer
  • Cancer
  • Prostatic Neoplasms
  • Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether [68Ga]Ga-HTK03149 PET/CT will improve 1 primary outcome and 3 secondary outcomes in patients with Disease Attributes. Measurement will happen over the course of Before injection, 1 hours post injection, 2 hours post injection and 2.5 hours post injection.

18-72 hours
Number of participants with self-reported 68Ga-HTK03149 related adverse event
Hour 5
Number of participants with 68Ga-HTK03149 related adverse events as assessed by abnormal vital sign measurement
Up to 12 months
Biodistribution of 68Ga-HTK03149 PET/CT in human subjects
Perform a preliminary assessment of 68Ga-HTK03149 uptake in prostate cancer lesions

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Control
[68Ga]Ga-HTK03149 PET/CT

This trial requires 10 total participants across 2 different treatment groups

This trial involves 2 different treatments. [68Ga]Ga-HTK03149 PET/CT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

[68Ga]Ga-HTK03149 PET/CT
Other
200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 12 months for reporting.

Closest Location

BC Cancer - Vancouver, Canada

Eligibility Criteria

This trial is for male patients aged 18 and older. You must have received newly diagnosed for Disease Attributes or one of the other 5 conditions listed above. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
People who have been diagnosed with prostate cancer and who have at least one measurable lesion based on a CT scan, MR scan, or an 18F-DCFPyL or 68Ga-PSMA-11 PET scan are eligible to participate. show original
The patient has an ECOG performance status of 2 or less. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of disease attributes?

Add answer

Signs of disease attributes include an increased likelihood of developing disease attributes, a decreased mean time to diagnoses, and higher cost of disease care over time.

Unverified Answer

What is disease attributes?

Add answer

It is important to consider the following disease attributes to enable an efficient evaluation of disease in its clinical context. The patient-centred approach is recommended especially for evaluating the disease process.

Unverified Answer

Can disease attributes be cured?

Add answer

Although we did not find a significant association between disease attributes and survival, we did identify factors associated with better outcomes. Clinicians should continue to use clinical judgment to prioritize patient outcomes and allocate resources appropriately.

Unverified Answer

What causes disease attributes?

Add answer

There are a number of theories that would propose possible causative mechanisms. While there is circumstantial evidence for the [hypermagenesis theory, the mechanism by which it explains phenotypic observations remains unknown and needs to be investigated further.\n

Unverified Answer

What are common treatments for disease attributes?

Add answer

This large analysis supports the notion that treatments are used for different aspects of disease, not in a homogenous manner. Further, if patients with disease attributes are asked why they choose a particular treatment, there is not a uniform response. Instead, treatment has been selected based on aspects that are associated with having one type of treatment compared to another, including type characteristics, age, and disease stage.

Unverified Answer

How many people get disease attributes a year in the United States?

Add answer

Only 5% of Americans are affected with at least one medical condition listed in the ICD-10. This is below the 12% of American adults who are reported to have chronic medical conditions in the US National Health Interview Survey.

Unverified Answer

What is the survival rate for disease attributes?

Add answer

Most disease attributes do not have significant survival differentatiosn. Those with a higher grade of disease, those with a higher stage of disease at time of disease attributes, those whose disease is sporadic, and those whose disease is present for a longer time have an increased risk of death.

Unverified Answer

Has [68ga]ga-htk03149 pet/ct proven to be more effective than a placebo?

Add answer

There were no significant differences between 68Ga-HTk03149 PET/CT and CTR. This suggests that 68Ga-HTk03149 PET/CT provided useful information regardless of the PET/CT findings in patients with metastatic tumor sites. Findings from a recent study presented herein do not support the use of [(68)Ga]ga-HTk03149 PET/CT in clinical practice.

Unverified Answer

What are the chances of developing disease attributes?

Add answer

With this risk adjustment model, the relative risks across groups and the predicted probabilities of developing disease attributes are similar. Also, we find no evidence of non-random measurement error.

Unverified Answer

What does [68ga]ga-htk03149 pet/ct usually treat?

Add answer

• 68Ga PET can help find the causes of pet/cts. • The most common cause of pet/ct is a tumour. • The most common cause of a PET anomaly is FDG uptake by the liver. • 68Ga PET might be a useful tool for making the diagnosis and assessment of the disease.

Unverified Answer

How quickly does disease attributes spread?

Add answer

The pattern of spread did not match the previously hypothesized model based on the assumptions about the initial spread. Based on this work, we find that the spread pattern of RA-related autoantibodies is similar to that of other RA-related autoimmune diseases found in other populations, and that RA-related autoimmune diseases generally do not spread in any predetermined fashion, such as along family lines. Findings from a recent study also support that RA may be a single disease that can exhibit disease attributes such as severity and rheumatoid factor positivity.

Unverified Answer

How serious can disease attributes be?

Add answer

When one considers the extent of potential economic harm to the American population, and the degree to which the disease burden currently reflects the economic cost of health care expenditures, and the impact of major advances in medical care, the impact of chronic disease is probably substantial.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Disease Attributes by sharing your contact details with the study coordinator.